KLDO Share Price Performance
US$0
-0.00 (-100.00%)
Price US$0
Share Pricen/a
Kaleido Biosciences, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
KLDO Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Kaleido Biosciences, Inc. Key Details
About KLDO
- Founded
- 2015
- Employees
- n/a
- CEO
- WebsiteView website
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of ulcerative colitis, psoriasis, atopic immune disease, chronic obstructive pulmonary disease pathogens, and immuno-oncology. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
